SG11201700703XA - Salt of monocyclic pyridine derivative and crystal thereof - Google Patents

Salt of monocyclic pyridine derivative and crystal thereof

Info

Publication number
SG11201700703XA
SG11201700703XA SG11201700703XA SG11201700703XA SG11201700703XA SG 11201700703X A SG11201700703X A SG 11201700703XA SG 11201700703X A SG11201700703X A SG 11201700703XA SG 11201700703X A SG11201700703X A SG 11201700703XA SG 11201700703X A SG11201700703X A SG 11201700703XA
Authority
SG
Singapore
Prior art keywords
salt
crystal
pyridine derivative
monocyclic pyridine
monocyclic
Prior art date
Application number
SG11201700703XA
Other languages
English (en)
Inventor
Shunsuke Ozaki
Kenshi Yoshida
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201700703XA publication Critical patent/SG11201700703XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SG11201700703XA 2014-08-18 2015-08-17 Salt of monocyclic pyridine derivative and crystal thereof SG11201700703XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014166118 2014-08-18
PCT/JP2015/073047 WO2016027781A1 (ja) 2014-08-18 2015-08-17 単環ピリジン誘導体の塩およびその結晶

Publications (1)

Publication Number Publication Date
SG11201700703XA true SG11201700703XA (en) 2017-03-30

Family

ID=55350725

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700703XA SG11201700703XA (en) 2014-08-18 2015-08-17 Salt of monocyclic pyridine derivative and crystal thereof

Country Status (14)

Country Link
US (1) US9951047B2 (ko)
EP (1) EP3184520B1 (ko)
JP (1) JP5925978B1 (ko)
KR (1) KR102344105B1 (ko)
CN (1) CN106660997B (ko)
AU (1) AU2015304465B2 (ko)
BR (1) BR112017002268B1 (ko)
CA (1) CA2956270C (ko)
ES (1) ES2914072T3 (ko)
IL (1) IL250290B (ko)
MX (1) MX369646B (ko)
RU (1) RU2658821C1 (ko)
SG (1) SG11201700703XA (ko)
WO (1) WO2016027781A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001969C (en) * 2015-12-17 2023-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
MX2020002083A (es) * 2017-10-12 2020-03-24 Eisai R&D Man Co Ltd Composicion farmaceutica que comprende un inhibidor tirosina cinasa selectivo para receptores del factor de crecimiento de fibroblastos (fgfr).
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
CA3180128A1 (en) 2020-04-17 2021-10-21 Eisai R&D Management Co., Ltd. Breast cancer therapeutic agent
CA3185174A1 (en) 2020-07-31 2022-02-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
EP4209216A1 (en) 2020-10-28 2023-07-12 Eisai R&D Management Co., Ltd Pharmaceutical composition for treating tumors
JP7315805B1 (ja) * 2021-08-31 2023-07-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の合成中間体の製造方法
CA3227540A1 (en) * 2021-08-31 2023-03-09 Eisai R&D Management Co., Ltd. Method for producing monocyclic pyridine derivative
CN116768856A (zh) * 2022-03-18 2023-09-19 上海润石医药科技有限公司 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
ES2282299T3 (es) * 2000-10-20 2007-10-16 EISAI R&D MANAGEMENT CO., LTD. Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
BR0313871A (pt) 2002-08-30 2005-07-19 Eisai Co Ltd Derivados aromáticos contendo nitrogênio
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN100497339C (zh) 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
WO2006127926A2 (en) 2005-05-23 2006-11-30 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008078100A2 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
WO2009001065A1 (en) 2007-06-25 2008-12-31 Qinetiq Limited Preconcentrator device incorporating a polymer of intrinsic microporosity
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
CL2008003675A1 (es) 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
UA103478C2 (ru) 2008-05-23 2013-10-25 Новартіс Аг Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
JP2011524888A (ja) 2008-06-19 2011-09-08 アストラゼネカ アクチボラグ ピラゾール化合物４３６
BRPI0923786C8 (pt) 2008-12-30 2021-05-25 Arqule Inc compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
WO2010078427A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
CA2748174A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
US8829199B2 (en) 2009-08-07 2014-09-09 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivative
ES2524548T3 (es) 2009-10-30 2014-12-10 Novartis Ag N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
MY192354A (en) 2011-07-19 2022-08-17 Merck Sharp & Dohme 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
PT2657233E (pt) 2012-01-19 2014-10-24 Taiho Pharmaceutical Co Ltd Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal
EP2821402B1 (en) 2012-02-28 2019-08-21 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
CN104619840A (zh) 2012-07-05 2015-05-13 日本国立癌症研究中心 Fgfr2融合基因
KR102163776B1 (ko) 2012-07-11 2020-10-12 블루프린트 메디신즈 코포레이션 섬유아세포 성장인자 수용체의 저해제
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Also Published As

Publication number Publication date
BR112017002268A2 (pt) 2017-11-21
AU2015304465A1 (en) 2017-02-23
CN106660997B (zh) 2019-05-21
EP3184520A1 (en) 2017-06-28
CA2956270C (en) 2022-08-09
EP3184520B1 (en) 2022-03-23
US20170217935A1 (en) 2017-08-03
CN106660997A (zh) 2017-05-10
EP3184520A4 (en) 2018-04-18
IL250290B (en) 2020-06-30
KR102344105B1 (ko) 2021-12-29
JP5925978B1 (ja) 2016-05-25
ES2914072T3 (es) 2022-06-07
WO2016027781A1 (ja) 2016-02-25
KR20170035927A (ko) 2017-03-31
AU2015304465B2 (en) 2019-05-09
CA2956270A1 (en) 2016-02-25
US9951047B2 (en) 2018-04-24
MX369646B (es) 2019-11-15
IL250290A0 (en) 2017-03-30
RU2658821C1 (ru) 2018-06-25
MX2017001624A (es) 2017-04-27
BR112017002268B1 (pt) 2022-11-08
JPWO2016027781A1 (ja) 2017-04-27

Similar Documents

Publication Publication Date Title
GB2542881B (en) Crystal forms of ß-nicotinamide mononucleotide
IL250290A0 (en) A salt of a monocyclic pyridine derivative and its crystalline form
HRP20190432T1 (hr) Spojevi pladienolid piridina i postupci uporabe
HK1245774A1 (zh) Copanlisib及其二鹽酸鹽的合成
HRP20190527T1 (hr) Sinteza kopanlisiba i njegove dihidrokloridne soli
SG11201507897SA (en) Salt of pyrazoloquinoline derivative, and crystal thereof
ZA201701066B (en) Pyridine derivatives and anti-mycobacterial use thereof
IL253018A0 (en) Crystalline forms of apomorphine and their uses
EP3107540A4 (en) Polymorphs of lomitapide and its salts
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
ZA201901155B (en) Salt and crystal of diaza-benzofluorane compound
AU2014901403A0 (en) Combination of crystals and water